STOCK TITAN
  1. Home
  2. News
  3. BIAF

BioAffinity Technologies Inc - BIAF STOCK NEWS

IMPACT
SENTIMENT
BIAF : Nasdaq BIAFW : Nasdaq
bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research
clinical trial
IMPACT
SENTIMENT
BIAF : Nasdaq BIAFW : Nasdaq
bioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer Treatments
IMPACT
SENTIMENT
BIAF : Nasdaq
Argus Research Initiates Equity Research Report Coverage on bioAffinity Technologies, Inc. (NasdaqCM: BIAF)
IMPACT
SENTIMENT
BIAF : Nasdaq BIAFW : Nasdaq
bioAffinity Technologies Expands Diagnostic Division with Promotions and New Hires to Strengthen Clinical Bench
management
IMPACT
SENTIMENT
BIAF : Nasdaq BIAFW : Nasdaq
bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting
IMPACT
SENTIMENT
BIAF : Nasdaq BIAFW : Nasdaq
bioAffinity Technologies Reports Third Quarter 2022 Financial Results and Provides Business Update
earnings
IMPACT
SENTIMENT
BIAF : Nasdaq BIAFW : Nasdaq
bioAffinity Technologies Announces Sheila Habib, MD and David Hill, MD Join the Company’s Scientific and Medical Advisory Board
management
IMPACT
SENTIMENT
BIAF : Nasdaq BIAFW : Nasdaq
bioAffinity Technologies to Report Third Quarter 2022 Financial Results
conferences earnings
IMPACT
SENTIMENT
BIAF : Nasdaq BIAFW : Nasdaq
bioAffinity Technologies Announces Award of Therapeutic Patents in China, Mexico and Australia
IMPACT
SENTIMENT
BIAF : Nasdaq BIAFW : Nasdaq
bioAffinity Technologies Presents Results from Flow Cytometry Analysis of the Lung at CHEST Conference
Stock BIAF logo
BioAffinity Technologies Inc

Nasdaq:BIAF

BIAF Rankings

#7019 Ranked by Market Cap
#4738 Ranked by Stock Gains
N/A Ranked by Dividends

BIAF Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
San Antonio

About BIAF

addressing a critical need to find cancer early and treat cancer specifically bioaffinity technologies, inc. develops tests and therapies to detect and treat cancer at the cellular level. our first product, cypath® flow cytometry for lung cancer (cypath® lung), has been licensed by precision pathology services for continued development and commercial sale as a laboratory developed test. cypath® lung has the potential to dramatically increase overall diagnostic accuracy leading to increased survival, fewer unnecessary invasive procedures and lower patient anxiety and medical costs.